Relapsed or Refractory Peripheral T-cell Lymphoma Clinical Trial
Official title:
A Phase II, Open-label, Single-arm, Multicenter Study of Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
This is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL.
This is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL. To determine eligibility, subjects must have PTCL confirmed with a sample or specimen evaluated by the investigator.A treatment cycle is defined as 4 weeks. All eligible subjects will be treated with chidamide until disease progression, intolerable toxicity effects, death, or withdrawal of consent. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03356678 -
Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma
|
N/A | |
| Completed |
NCT02464228 -
Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy.
|
Phase 2 | |
| Recruiting |
NCT04108325 -
A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04329130 -
Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
|
Phase 2 |